Skip to main content

Search

Reset all filters
319 Result(s)
Sort by

Agreement-to-acquire-Labor-Dr.-Merk

Agreement-to-acquire-Labor-Dr.-Merk

Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
RE-LY-trial-publication-10-year-anniversary

RE-LY-trial-publication-10-year-anniversary

Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Neovascular AMD (wet AMD)

Neovascular AMD (wet AMD)

Neovascular AMD (or wet AMD) is a severe form of advanced age-related macular degeneration that can lead to irreversible vision loss if untreated
Immunology

Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Grass Roots

Grass Roots

Grass Roots Innovation: Championing the Next Generation of Life-Science Innovators
Geographic Atrophy

Geographic Atrophy

Geographic atrophy (GA) is an advanced and severe form of dry age-related macular degeneration (AMD) that progresses slowly but can lead to permanent vision loss.
Open Innovation at Boehringer Ingelheim

Open Innovation at Boehringer Ingelheim

Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Vargatef®

Vargatef®

Combination therapy with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
Future of Diabetes

Future of Diabetes

This video highlights the evolution of type 2 diabetes management
Giotrif®

Giotrif®

For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist